BioRegenx, Inc. (BRGX)
OID · Healthcare · Health Information Services
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About BioRegenx, Inc.
BioRegenx, Inc. engages in the research, development, and commercialization of dietary supplements, medical devices, software, and contactless diagnostic technologies in the United States and internationally. The company offers DocSun AI engine, which integrates with a ballistocardiograph that detects an individual's heartbeat; TruScan.AI mobile app for additional health indications; VitalWellness app for DNA and epigenetics platform; and Endocalyx Pro, a dietary supplement targeting microvascular capillary health. It also provides MyBodyRx, a supplement; GlycoCheck software and medical devices; hydrogen water products and health and wellness devices, such as pulsed electro-magnetic field devices; StimaWELL and ReLounge electronic muscle stimulation therapy devices; and Findit.com, a social media content management platform. The company sells its products through a direct selling channel to health professionals and research organizations. BioRegenx, Inc. is headquartered in Chattanooga, Tennessee.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 446K | 508K | 386K | 426K |
| Gross Profit | 352K | 426K | 319K | 348K |
| Operating Income | -106K | -8K | -211K | -50K |
| Net Income | -178K | -81K | -1.0M | -26K |
| Diluted EPS | $0.00 | $0.00 | $nan | $0.00 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 42K | 3.4M | 2.3M | 1.9M |
| Gross Profit | 42K | 2.3M | 1.7M | 1.5M |
| Operating Income | -78K | -3.4M | -6.6M | -519K |
| Net Income | -78K | -3.6M | -23.1M | -1.5M |
| Diluted EPS | $-0.00 | $-0.01 | $-0.03 | $0.00 |